Efficacy of pyruvate therapy in patients with mitochondrial disease: a semi-quantitative clinical evaluation study
T Fujii, F Nozaki, K Saito, A Hayashi, Y Nishigaki… - Molecular genetics and …, 2014 - Elsevier
Background Disorders of oxidative phosphorylation (OXPHOS) cause an increase in the
NADH/NAD+ ratio, which impairs the glycolysis pathway. Treatment with pyruvate is
expected to decrease the ratio and thereby restore glycolysis. There are some case reports
on the efficacy of pyruvate treatment for mitochondrial diseases. However, few of these
reports assessed their results using a standardized scale. Methods We monitored 4
bedridden patients with OXPHOS disorders who continued therapies of 0.5–1.0 g/kg/day of …
NADH/NAD+ ratio, which impairs the glycolysis pathway. Treatment with pyruvate is
expected to decrease the ratio and thereby restore glycolysis. There are some case reports
on the efficacy of pyruvate treatment for mitochondrial diseases. However, few of these
reports assessed their results using a standardized scale. Methods We monitored 4
bedridden patients with OXPHOS disorders who continued therapies of 0.5–1.0 g/kg/day of …